Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Maintenance Atezolizumab for Stage IB-IIIA NSCLC
Open-label, randomized, phase 3 trial (IMpower010) Completely resected stage IB-IIIA NSCLC after adjuvant platinum-based chemotherapy Atezolizumab (1,200 mg q3w for 16 cycles) vs.
New Protocol: Maintenance Sacituzumab Govitecan with Avelumab for Urothelial Carcinoma
Phase 2, randomized, open-label trial (JAVELIN Bladder Medley) Locally advanced or metastatic urothelial carcinoma without progression after first-line platinum-based chemotherapy
New Indication: Daratumumab for High-Risk Smoldering Myeloma
Phase 3, open-label, multicenter, randomized trial (AQUILA) Patients with high-risk smoldering multiple myeloma without end-organ damage Daratumumab subcutaneous monotherapy vs. ac
New Reference: Encorafenib, Cetuximab with FOLFOX for bRAF Mutated Metastatic Colorectal Cancer
Open-label, randomized, phase 3 trial (BREAKWATER) Untreated BRAF V600E–mutated metastatic colorectal cancer Encorafenib + cetuximab + mFOLFOX6 vs. investigator’s choice of che
New Reference: Enfortumab Vedotin + Pembrolizumab for Advanced Urothelial Carcinoma
Phase 3, global, open-label randomized trial (EV-302/KEYNOTE-A39) Untreated locally advanced or metastatic urothelial carcinoma (cisplatin-eligible or ineligible) Enfortumab vedoti
New Reference: Enzalutamide with Radium-223 for Prostate Cancer
Phase 3, randomized, open-label, international trial (PEACE-3) mCRPC with bone metastases, no visceral metastases, asymptomatic or mildly symptomatic Enzalutamide 160 mg daily vs.
New Reference: Inavolisib with Palbociclib and Fulvestrant for Advanced ER+ Breast Cancer
Phase 3, double-blind, randomized trial (INAVO120) PIK3CA-mutated, HR+/HER2− locally advanced or metastatic breast cancer relapsed during or within 12 mos after adjuvant endocrin
New Indication: Ipilimumab/Nivolumab for Unresectable HCC
Phase 3, open-label, global, randomized trial (CheckMate 9DW) Previously untreated unresectable hepatocellular carcinoma Nivolumab + ipilimumab q3w x4 doses then nivolumab q4w vs.
New Reference: Relatlimab/Nivolumab for Melanoma
Phase 2/3, global, randomized, open-label trial (RELATIVITY-047) Previously untreated, unresectable or metastatic stage III/IV melanoma Nivolumab 480 mg + relatlimab 160 mg q4w vs.
